AUTL - BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

2024-02-22 19:04:44 ET

Summary

• BioNTech and Autolus have announced a strategic alliance to advance their autologous CAR-T programs toward market authorization.
• BioNTech, known for its COVID-19 vaccine, is diverting its focus back to oncology and has a diverse, but immature pipeline in the field.
• Autolus, with its lead candidate Obe-Cel, is awaiting FDA approval and could potentially become a new standard of care in relapsed or refractory acute lymphocytic leukemia.
• BioNTech has made a $200m equity investment into Autolus as part of the deal. It would make sense for the cash-rich company to complete a full acquisition, in my view.

Investment Overview - BioNTech, Autolus Join Forces On Autologous CAR-T

Mainz, Germany-based BioNTech SE ( BNTX ) and London-based Autolus Therapeutics plc ( AUTL ) announced on Feb. 8 that they will join forces and embark on a strategic alliance "with the aim to advance both companies' autologous CAR-T programs towards the market, pending market authorization."...

For further details see: